BGJ398

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

MelanomaUrothelial CarcinomaCholangiocarcinomaGastrointestinal Stromal Tumor

947 competitors in Melanoma

#DrugCompanyPhaseTrials

1

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

102

CC 5013

Bristol-Myers Squibb

Phase 3

33

Methylphenidate Hydrochloride

Takeda

Phase 3

14

GSK 257049

GSK

Phase 3

15

ABP 234

Amgen

Phase 3

16

Adjuvant Therapy

FFudan University

Phase 3

17

BGJ398

Novartis

Phase 3

18

Anti-PD1

Pfizer

Phase 3

19

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

3910

Intron a

Merck & Co.

Preclinical

4Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cholangiocarcinoma2 trials

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Terminated·QQED Therapeutics, a BridgeBio company·Phase 3·NCT03773302·48 enrolled

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Terminated·QQED Therapeutics, a BridgeBio company·Phase 2·NCT02150967·143 enrolled

Recurrent1 trial

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Completed·Novartis·Phase 2·NCT01975701·26 enrolled

Gastrointestinal Stromal Tumor1 trial

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02257541·16 enrolled

Other Solid Tumors1 trial

Ph Ib/BGJ398/Cervix and Other Solid Tumors

Withdrawn·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT02312804

Tumors1 trial

BGJ398 for Patients With Tumors With FGFR Genetic Alterations

Terminated·Novartis·Phase 2·NCT02160041·84 enrolled

7 more indications

Melanoma1 trial

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Completed·Pfizer·Phase 2·NCT02159066·158 enrolled

Tumor-Induced Osteomalacia1 trial

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

Terminated·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT03510455·4 enrolled

Urothelial Carcinoma1 trial

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT02657486·4 enrolled

Recurrent Head and Neck Cancer1 trial

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Terminated·UUniversity of Chicago·Phase 2·NCT02706691·1 enrolled

Oral1 trial

A Phase I Study of Oral BGJ398 in Asian Patients

Completed·Novartis·Phase 1·NCT01697605·9 enrolled

Solid Tumors1 trial

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Completed·Novartis·Phase 1·NCT01928459·62 enrolled

Advanced Solid Malignancies1 trial

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Completed·Novartis·Phase 1·NCT01004224·208 enrolled

Details

Drug Info

Related News